540 related articles for article (PubMed ID: 32550761)
1. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
[TBL] [Abstract][Full Text] [Related]
2. Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection.
Mak LY; Wong DK; Seto WK; Ning Q; Cheung KS; Fung J; Lai CL; Yuen MF
Hepatol Int; 2019 Mar; 13(2):148-156. PubMed ID: 30671807
[TBL] [Abstract][Full Text] [Related]
3. Changes in Liver Stiffness and Noninvasive Fibrosis Scores in Egyptian Adolescents Successfully Treated with Ledipasvir-Sofosbuvir for Chronic Hepatitis C Virus Infection.
Fahmy DM; Shokeir M; El Zeiny SM; Jonas MM; Abdallah A
J Pediatr; 2021 Apr; 231():110-116. PubMed ID: 33347957
[TBL] [Abstract][Full Text] [Related]
4. Direct-acting antiviral agents in the treatment of chronic hepatitis C-Real-life experience from clinical practices in Pakistan.
Mushtaq S; Mansoor A; Umar M; Khan A; Siddiqi S; Manzoor S
J Med Virol; 2020 Dec; 92(12):3475-3487. PubMed ID: 32129507
[TBL] [Abstract][Full Text] [Related]
5. Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy.
Nagata H; Nakagawa M; Nishimura-Sakurai Y; Asano Y; Tsunoda T; Miyoshi M; Kaneko S; Goto F; Otani S; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Azuma S; Kakinuma S; Tojo N; Tohda S; Asahina Y; Watanabe M;
Hepatol Int; 2016 Nov; 10(6):956-964. PubMed ID: 27435935
[TBL] [Abstract][Full Text] [Related]
6. Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection.
Cordie A; Elsharkawy A; Abdel Alem S; Meshaal S; El Akel W; Abdellatif Z; Kamal W; Al Askalany M; Kamel S; Abdel Aziz H; Kandeel A; Esmat G
Trans R Soc Trop Med Hyg; 2020 Apr; 114(4):232-240. PubMed ID: 31925434
[TBL] [Abstract][Full Text] [Related]
7. Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
Uchida Y; Naiki K; Kouyama JI; Sugawara K; Nakao M; Motoya D; Inao M; Nakayama N; Imai Y; Tomiya T; Mochida S
PLoS One; 2018; 13(10):e0205600. PubMed ID: 30308053
[TBL] [Abstract][Full Text] [Related]
8. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection.
Mak LY; Wong DK; Cheung KS; Seto WK; Lai CL; Yuen MF
Clin Transl Gastroenterol; 2018 Jun; 9(6):163. PubMed ID: 29915243
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
Margusino-Framiñán L; Cid-Silva P; Mena-de-Cea A; Rodríguez-Osorio I; Pernas-Souto B; Delgado-Blanco M; Pertega-Díaz S; Martín-Herranz I; Castro-Iglesias A
Rev Esp Quimioter; 2019 Apr; 32(2):137-144. PubMed ID: 30761823
[TBL] [Abstract][Full Text] [Related]
10. Diabetic patients with chronic hepatitis C virus response compared to non diabetics when treated with directly acting antiviral therapy.
Marzaban RN; AlMekhzangy HI; ElAkel W; ElBaz TM; ElShazly YM; ElSaeed K; Anees M; Said M; ElSerafy MA; Esmat GG; Doss WH
Arab J Gastroenterol; 2024 May; 25(2):118-124. PubMed ID: 38378359
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.
Nagaty A; Helmy SH; Abd El-Wahab EW
Trans R Soc Trop Med Hyg; 2020 Feb; 114(3):200-212. PubMed ID: 31722032
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: A prospective observational study.
Nozaki A; Chuma M; Hara K; Moriya S; Fukuda H; Numata K; Tanaka K; Morimoto M; Sakamaki K; Yamanaka T; Kondo M; Maeda S
Medicine (Baltimore); 2021 Mar; 100(12):e25110. PubMed ID: 33761674
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases.
Moon HW; Park M; Hur M; Kim H; Choe WH; Yun YM
Ann Lab Med; 2018 Jul; 38(4):331-337. PubMed ID: 29611383
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C.
Xu H; Kong W; Liu L; Chi X; Wang X; Wu R; Gao X; Wang H; Qu L; Qi Y; Pan Y; Niu J
BMC Gastroenterol; 2017 May; 17(1):62. PubMed ID: 28486931
[TBL] [Abstract][Full Text] [Related]
16. Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients.
Abdel Alem S; Elsharkawy A; El Akel W; Abdelaziz AO; Salama RM; El-Sayed MH; El Kassas M; Anees M; Shedeed M; Abdelsalam F; Ziada DH; El Shazly Y; El-Serafy M; Waked I; Esmat G; Doss W
Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):1009-1016. PubMed ID: 31418303
[No Abstract] [Full Text] [Related]
17. Serum Mac-2-binding protein glycosylation isomer predicts esophagogastric varices in cirrhotic patients with chronic hepatitis C virus infection treated with IFN-free direct-acting antiviral agent: M2BPGi levels predict varices in SVR patients.
Kikukawa K; Uchida-Kobayashi S; Tamori A; Yoshida K; Kotani K; Motoyama H; Kozuka R; Hagihara A; Fujii H; Morikawa H; Enomoto M; Murakami Y; Kawada N
Ann Hepatol; 2020; 19(4):367-372. PubMed ID: 32444247
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of Mac-2 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis in health checkups.
Nah EH; Cho S; Kim S; Kim HS; Cho HI
J Clin Lab Anal; 2020 Aug; 34(8):e23316. PubMed ID: 32227396
[TBL] [Abstract][Full Text] [Related]
19. Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection.
Ueda N; Kawaoka T; Imamura M; Aikata H; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Hayes CN; Yokozaki M; Chayama K
BMC Gastroenterol; 2020 Sep; 20(1):314. PubMed ID: 32977741
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study.
Li J; Wu DB; Jiang W; Chen XB; Xiao GB; Wang YH; Wang ML; Tao YC; Chen EQ
Medicine (Baltimore); 2020 Oct; 99(43):e22726. PubMed ID: 33120769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]